1. Faron ML, Ledeboer NA, Buchan BW. Resistance mechanisms, epidemiology, and approaches to screening for vancomycin-resistant enterococcus in the health care setting. J Clin Microbiol. 2016; 54:2436–47.
Article
2. Puchter L, Chaberny IF, Schwab F, Vonberg RP, Bange FC, Ebadi E. Economic burden of nosocomial infections caused by vancomycin-resistant enterococci. Antimicrob Resist Infect Control. 2018; 7:1.
Article
3. Kauffman CA. Therapeutic and preventative options for the management of vancomycin-resistant enterococcal infections. J Antimicrob Chemother. 2003; 51(Suppl 3):iii23–30.
Article
4. Lloyd-Smith P, Younger J, Lloyd-Smith E, Green H, Leung V, Romney MG. Economic analysis of vancomycin-resistant enterococci at a Canadian hospital: assessing attributable cost and length of stay. J Hosp Infect. 2013; 85:54–9.
Article
5. Shenoy ES, Paras ML, Noubary F, Walensky RP, Hooper DC. Natural history of colonization with methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin-resistant Enterococcus (VRE): a systematic review. BMC Infect Dis. 2014; 14:177.
6. Pereira GH, Muller PR, Zanella RC, de Jesus Castro Lima M, Torchio DS, Levin AS. Outbreak of vancomycin-resistant enterococci in a tertiary hospital: the lack of effect of measures directed mainly by surveillance cultures and differences in response between Enterococcus faecium and Enterococcus faecalis. Am J Infect Control. 2010; 38:406–9.
Article
7. Weinstein MR, Dedier H, Brunton J, Campbell I, Conly JM. Lack of efficacy of oral bacitracin plus doxycycline for the eradication of stool colonization with vancomycin-resistant Enterococcus faecium. Clin Infect Dis. 1999; 29:361–6.
Article
8. Trautner BW, Grigoryan L, Petersen NJ, Hysong S, Cadena J, Patterson JE, et al. Effectiveness of an antimicrobial stewardship approach for urinary catheter-associated asymptomatic bacteriuria. JAMA Intern Med. 2015; 175:1120–7.
Article
9. Chopra I, Roberts M. Tetracycline antibiotics: mode of action, applications, molecular biology, and epidemiology of bacterial resistance. Microbiol Mol Biol Rev. 2001; 65:232–60.
Article
10. Agwuh KN, MacGowan A. Pharmacokinetics and pharmacodynamics of the tetracyclines including glycylcyclines. J Antimicrob Chemother. 2006; 58:256–65.
Article
11. Holmes NE, Charles PG. Safety and efficacy review of doxycycline. Clin Med Ther. 2009; 1:471–82.
Article
12. Gupta K, Bhadelia N. Management of urinary tract infections from multidrug-resistant organisms. Infect Dis Clin North Am. 2014; 28:49–59.
Article
13. Wong AH, Wenzel RP, Edmond MB. Epidemiology of bacteriuria caused by vancomycin-resistant enterococci: a retrospective study. Am J Infect Control. 2000; 28:277–81.
14. Drees M, Snydman DR, Schmid CH, Barefoot L, Hansjosten K, Vue PM, et al. Prior environmental contamination increases the risk of acquisition of vancomycin-resistant enterococci. Clin Infect Dis. 2008; 46:678–85.
Article
15. Olivier CN, Blake RK, Steed LL, Salgado CD. Risk of vancomycin-resistant Enterococcus (VRE) bloodstream infection among patients colonized with VRE. Infect Control Hosp Epidemiol. 2008; 29:404–9.
16. Edmond MB, Ober JF, Dawson JD, Weinbaum DL, Wenzel RP. Vancomycin-resistant enterococcal bacteremia: natural history and attributable mortality. Clin Infect Dis. 1996; 23:1234–9.
Article
17. Edmond MB, Ober JF, Weinbaum DL, Pfaller MA, Hwang T, Sanford MD, et al. Vancomycin-resistant Enterococcus faecium bacteremia: risk factors for infection. Clin Infect Dis. 1995; 20:1126–33.
Article
18. Tornieporth NG, Roberts RB, John J, Hafner A, Riley LW. Risk factors associated with vancomycin-resistant Enterococcus faecium infection or colonization in 145 matched case patients and control patients. Clin Infect Dis. 1996; 23:767–72.
Article
19. Montecalvo MA, Shay DK, Patel P, Tacsa L, Maloney SA, Jarvis WR, et al. Bloodstream infections with vancomycin-resistant enterococci. Arch Intern Med. 1996; 156:1458–62.
Article
20. Weinstock DM, Conlon M, Iovino C, Aubrey T, Gudiol C, Riedel E, et al. Colonization, bloodstream infection, and mortality caused by vancomycin-resistant enterococcus early after allogeneic hematopoietic stem cell transplant. Biol Blood Marrow Transplant. 2007; 13:615–21.
Article
21. Choi HK, Kim KH, Lee SH, Lee SJ. Risk factors for recurrence of Clostridium difficile infection: effect of vancomycin-resistant enterococci colonization. J Korean Med Sci. 2011; 26:859–64.
Article
22. Dancer SJ. The problem with cephalosporins. J Antimicrob Chemother. 2001; 48:463–78.
Article
23. Shepard BD, Gilmore MS. Antibiotic-resistant enterococci: the mechanisms and dynamics of drug introduction and resistance. Microbes Infect. 2002; 4:215–24.
Article
24. Centers for Disease Control and Prevention. Antibiotic resistance threats in the United States, 2013. Atlanta (GA): Centers for Disease Control and Prevention;2013.
25. Sohn KM, Peck KR, Joo EJ, Ha YE, Kang CI, Chung DR, et al. Duration of colonization and risk factors for prolonged carriage of vancomycin-resistant enterococci after discharge from the hospital. Int J Infect Dis. 2013; 17:e240–6.
Article
26. Korea Centers for Disease Control and Prevention. Healthcare associated disease control management guideline. Cheongju (KR): Korea Centers for Disease Control and Prevention;2016.